BLCO Q3 2024: Q4 Outlook of 10% Organic Growth and 20% EBITDA Margin
- Robust launch cycle and innovation: The Q&A emphasized the company's commitment to a sustained and aggressive product launch cycle—including new products like Miebo, Xiidra, daily SiHy, and premium IOLs—which supports long‑term revenue and margin expansion.
- Effective direct-to-consumer marketing: Executives highlighted the early success of creative DTC campaigns (e.g., for Xiidra, Miebo, and Blink) that have already driven significant prescription growth and brand momentum, indicating strong market pull that could fuel future sales.
- Interconnected business model: The discussion pointed to a strategic blend across its Pharma, Surgical, Vision Care, and consumer segments that not only drives cross‑selling opportunities but also reinforces brand presence with eye care professionals, potentially translating to sustainable sales growth.
- Xiidra Headwinds: Concerns remain over Xiidra’s outlook due to uncertainties from the Inflation Reduction Act and evolving rebate dynamics, potentially weighing on its 2025 performance.
- Margin Pressure from Heavy Launch Investments: The significant investments in launching new products (such as Miebo, Xiidra, and premium IOLs) are currently compressing margins and delaying profitability improvements despite top-line growth.
- Consumer Channel Disruptions: Deterioration in retail channels—evidenced by destocking and issues like retailer inventory rebalancing and store closures—poses a risk to the sustainability of OTC and consumer sales performance.
-
Growth & Margins
Q: How will growth slow yet margins improve?
A: Management explained that Q4 guidance points to organic growth around 10% while EBITDA margins edge toward 20% due to favorable mix and seasonal acceleration, reinforcing their disciplined execution. -
Xiidra Headwinds
Q: What is Xiidra’s 2025 headwind impact?
A: They noted that while Xiidra continues strong volume at about 22,000 TRxs, evolving headwinds from the Inflation Reduction Act and rebate adjustments remain in play, though exact numbers weren’t provided. -
EBITDA Absorption
Q: Why hasn’t the top line boosted EBITDA yet?
A: Management attributed the constrained EBITDA to significant investments in a robust launch cycle, with the expectation that margins will improve as these new products mature. -
Prescription Valuation
Q: Do current investments affect EBITDA multiples?
A: They acknowledged that the Pharma segment’s lean EBITDA reflects strategic investments in products like Miebo and Xiidra, which—despite short-term dilution—are positioned to create long-term value alongside their strong Surgical and Vision Care businesses. -
DTC Timing
Q: When will DTC campaigns boost sales?
A: Management indicated that Xiidra’s DTC effort, now a few weeks old, is already showing promising TRx growth, and Miebo’s recent launch is expected to deliver similar benefits as its campaign matures. -
Execution Strategy
Q: What drives your strong execution?
A: They credited a clear, focused strategy on sales and operational excellence, which has delivered constant currency growth of about 19%, supported by a 10% organic increase, reinforcing the long-term strength of their approach. -
U.S. Contact Lenses
Q: How are U.S. contact lens sales doing?
A: Management reported solid growth in the U.S. with contact lenses up 13%, driven by the premium Daily SiHy portfolio, even as traditional product lines maintained steady performance amid retail sector challenges. -
Dry Eye Portfolio
Q: Is the dry eye pull-through sustainable?
A: They observed a robust 19% growth in the dry eye segment, with both OTC and prescription products contributing to an expanding, underpenetrated market, suggesting long-term sustainability. -
Clinician Messaging
Q: How are doctors combining Miebo and Xiidra?
A: Management explained that clinicians value the complementary benefits—Xiidra addressing inflammation and Miebo targeting evaporation—thus offering a holistic treatment approach for dry eye disease. -
Margin Guidance Specificity
Q: Are margins at risk of squeezing further?
A: The team maintained a balanced outlook with a target around 62.5%, noting that slight movement, such as 62.7% this quarter, is consistent with their evolving mix strategy and margin expansion plans.
Research analysts covering Bausch & Lomb.